A clinician's guide to double hit lymphomas

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 784-795

  Cheah, Chan Yoon ^a   Oki, Yasuhiro ^a   Westin, Jason R ^a   Turturro, Francesco ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B cell lymphoma unclassifiable; Diffuse large B cell lymphoma; Double hit lymphoma; MYC; Triple hit lymphoma

Indexed keywords

6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; BROMODOMAIN INHIBITOR; CPI 0610; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; SELINEXOR; UNCLASSIFIED DRUG; VENETOCLAX; VINCRISTINE; ANTINEOPLASTIC AGENT; MYC PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; DOUBLE HIT LYMPHOMA; DRUG CHOICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; INDUCTION CHEMOTHERAPY; ONCOGENE MYC; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; SINGLE HIT LYMPHOMA; SURVIVAL RATE; TRIPLE HIT LYMPHOMA; GENETICS; LYMPHOMA, B-CELL; METABOLISM; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE REARRANGEMENT, B-LYMPHOCYTE; GENES, BCL-2; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84924104202     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13276     Document Type: Review

References (70)

1. Aukema, S.M., Kreuz, M., Kohler, C.W., Rosolowski, M., Hasenclever, D., Hummel, M., Kuppers, R., Lenze, D., Ott, G., Pott, C., Richter, J., Rosenwald, A., Szczepanowski, M., Schwaenen, C., Stein, H., Trautmann, H., Wessendorf, S., Trumper, L., Loeffler, M., Spang, R., Kluin, P.M., Klapper, W., Siebert, R. & Molecular Mechanisms in Malignant Lymphomas Network Project. (2014) Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica, 99, 726-735.
2. Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E. & Jack, A. (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. Journal of Clinical Oncology, 28, 3360-3365.
3. Bertrand, P., Bastard, C., Maingonnat, C., Jardin, F., Maisonneuve, C., Courel, M.N., Ruminy, P., Picquenot, J.M. & Tilly, H. (2007) Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia, 21, 515-523.
4. Boerma, E.G., Siebert, R., Kluin, P.M. & Baudis, M. (2009) Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia, 23, 225-234.
5. Calado, D.P., Sasaki, Y., Godinho, S.A., Pellerin, A., Kochert, K., Sleckman, B.P., de Alboran, I.M., Janz, M., Rodig, S. & Rajewsky, K. (2012) The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nature Immunology, 13, 1092-1100.
6. Chang, T.C., Yu, D., Lee, Y.S., Wentzel, E.A., Arking, D.E., West, K.M., Dang, C.V., Thomas-Tikhonenko, A. & Mendell, J.T. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 40, 43-50.
7. Cheah, C.Y., Herbert, K.E., O'Rourke, K., Kennedy, G.A., George, A., Fedele, P.L., Gilbertson, M., Tan, S.Y., Ritchie, D.S., Opat, S.S., Prince, H.M., Dickinson, M., Burbury, K., Wolf, M., Januszewicz, E.H., Tam, C.S., Westerman, D.A., Carney, D.A., Harrison, S.J. & Seymour, J.F. (2014) A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer, 111, 1072-1079.
8. Davids, M.S., Seymour, J.F., Gerecitano, J.F., Kahl, B.S., Pagel, J.M., Wierda, W.G., Anderson, M.A., Rudersdorf, N., Gressick, L.A., Montalvo, N.P., Yang, J., Zhu, M., Dunbar, M., Cerri, E., Enschede, S.H., Humerickhouse, R. & Roberts, A.W. (2014) Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Journal of Clinical Oncology (ASCO Meeting Abstracts), 32, 8522.
9. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., Chesi, M., Schinzel, A.C., McKeown, M.R., Heffernan, T.P., Vakoc, C.R., Bergsagel, P.L., Ghobrial, I.M., Richardson, P.G., Young, R.A., Hahn, W.C., Anderson, K.C., Kung, A.L., Bradner, J.E. & Mitsiades, C.S. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 146, 904-917.
10. Dunleavy, K., Fanale, M., LaCasce, A., Noy, A., Caimi, P.F., Parekh, S., Hayslip, J.W., Jagadeesh, D., Lord, R.S., Lechowicz, M.J., Gaur, R., Lucas, A., Staudt, L.M., Steinberg, S.M., Kahl, B.S., Friedberg, J.W., Little, R.F., Bartlett, N.L. & Wilson, W.H. (2014) Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma In: ASH Annual Meeting Abstracts. In press.
11. Etchin, J., Sanda, T., Mansour, M.R., Kentsis, A., Montero, J., Le, B.T., Christie, A.L., McCauley, D., Rodig, S.J., Kauffman, M., Shacham, S., Stone, R., Letai, A., Kung, A.L. & Thomas Look, A. (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology, 161, 117-127.
12. Ferreri, A.J., Bruno-Ventre, M., Donadoni, G., Ponzoni, M., Citterio, G., Foppoli, M., Vignati, A., Scarfo, L., Sassone, M., Govi, S. & Caligaris-Cappio, F. (2014) Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. British Journal of Haematology. DOI: 10.1111/bjh.13194 [Epub ahead of print].
13. Filippakopoulos, P. & Knapp, S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nature Reviews. Drug Discovery, 13, 337-356.
14. Fiskvik, I., Beiske, K., Delabie, J., Yri, O., Spetalen, S., Karjalainen-Lindsberg, M.L., Leppa, S., Liestol, K., Smeland, E.B. & Holte, H. (2014) Combining MYC, BCL-2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leukaemia & Lymphoma, 1-18. [Epub ahead of print].
15. Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Moller, M.B. (2012a) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460-3467.
16. Green, T.M., Nielsen, O., de Stricker, K., Xu-Monette, Z.Y., Young, K.H. & Moller, M.B. (2012b) High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. American Journal of Surgical Pathology, 36, 612-619.
17. Gutierrez, M., Goy, A., Byrd, J.C., Flynn, J.M., Sorensen, M., Brown, P., Gabrail, N.Y., Savona, M., Flinn, I., Baz, R.C., Shah, B.D., Stone, R.M., Jacobsen, E., Kukreti, V., Tiedemann, R.E., Rashal, T., Mirza, M.R., Shacham, S., Kauffman, M. & Kuruvilla, J. (2014) A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology (ASCO Meeting Abstracts), 32, 8518.
18. Horn, H., Ziepert, M., Becher, C., Barth, T.F., Bernd, H.W., Feller, A.C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.L., Schmelter, C., Moller, P., Cogliatti, S., Pfreundschuh, M., Schmitz, N., Trumper, L., Siebert, R., Loeffler, M., Rosenwald, A., Ott, G. & German High-Grade Non-Hodgkin Lymphoma Study Group. (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood, 121, 2253-2263.
19. Horn, H., Staiger, A.M., Vohringer, M., Hay, U., Campo, E., Rosenwald, A., Ott, G. & Ott, M.M. (2014) Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations. American Journal of Surgical Pathology. DOI 10.1097/PAS.0000000000000319 [Epub ahead of print].
20. Howlett, C., Landsburg, D.J., Chong, E., Snedecor, S.J., Schuster, S., Green, T.M., Cohen, J.B., Svoboda, J., Nasta, S., Feldman, T., Rago, A., Land, D., Walsh, K.M., Goy, A. & Mato, A.R. (2014) Front-line Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 patients with Double-Hit Lymphomas: A Systematic Review and Meta-Analysis. In: ASH Annual Meeting Abstracts. In press.
21. Hu, S., Xu-Monette, Z.Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.M., Visco, C., Li, Y., Miranda, R.N., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W., Zhao, X., van Krieken, J.H., Huang, Q., Huh, J., Ai, W., Ponzoni, M., Ferreri, A.J., Zhou, F., Slack, G.W., Gascoyne, R.D., Tu, M., Variakojis, D., Chen, W., Go, R.S., Piris, M.A., Moller, M.B., Medeiros, L.J. & Young, K.H. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 121, 4021-4031; quiz 4250.
22. Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.F., Bernd, H.W., Cogliatti, S.B., Dierlamm, J., Feller, A.C., Hansmann, M.L., Haralambieva, E., Harder, L., Hasenclever, D., Kuhn, M., Lenze, D., Lichter, P., Martin-Subero, J.I., Moller, P., Muller-Hermelink, H.K., Ott, G., Parwaresch, R.M., Pott, C., Rosenwald, A., Rosolowski, M., Schwaenen, C., Sturzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H.H., Spang, R., Loeffler, M., Trumper, L., Stein, H., Siebert, R. & Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New England Journal of Medicine, 354, 2419-2430.
23. Johnson, N.A., Savage, K.J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J.M., Gascoyne, R.D. & Horsman, D.E. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114, 2273-2279.
24. Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452-3459.
25. Kanungo, A., Medeiros, L.J., Abruzzo, L.V. & Lin, P. (2006) Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Modern Pathology, 19, 25-33.
26. Karsan, A., Gascoyne, R.D., Coupland, R.W., Shepherd, J.D., Phillips, G.L. & Horsman, D.E. (1993) Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leukaemia & Lymphoma, 10, 433-441.
27. Klapper, W., Stoecklein, H., Zeynalova, S., Ott, G., Kosari, F., Rosenwald, A., Loeffler, M., Trumper, L., Pfreundschuh, M., Siebert, R. & German High-Grade Non-Hodgkin's Lymphoma Study Group. (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia, 22, 2226-2229.
28. Kluk, M.J., Chapuy, B., Sinha, P., Roy, A., Dal Cin, P., Neuberg, D.S., Monti, S., Pinkus, G.S., Shipp, M.A. & Rodig, S.J. (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One, 7, e33813.
29. Landsburg, D.J., Nasta, S.D., Svoboda, J., Morrissette, J.J. & Schuster, S.J. (2014) 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. British Journal of Haematology, 166, 369-374.
30. Le Gouill, S., Talmant, P., Touzeau, C., Moreau, A., Garand, R., Juge-Morineau, N., Gaillard, F., Gastinne, T., Milpied, N., Moreau, P., Harousseau, J.L. & Avet-Loiseau, H. (2007) The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica, 92, 1335-1342.
31. Lin, C.Y., Loven, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, T.I. & Young, R.A. (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell, 151, 56-67.
32. Mationg-Kalaw, E., Tan, L.H., Tay, K., Lim, S.T., Tang, T., Lee, Y.Y. & Tan, S.Y. (2012) Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology, 61, 1214-1218.
33. Meyer, N. & Penn, L.Z. (2008) Reflecting on 25 years with MYC. Nature Reviews Cancer, 8, 976-990.
34. Mitelman, F., Johansson, B. & Mertens, F. (Eds.) (2014) Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
35. Murphy, D.J., Junttila, M.R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D.A., Brown-Swigart, L., Johnson, L. & Evan, G.I. (2008) Distinct thresholds govern Myc's biological output in vivo. Cancer Cell, 14, 447-457.
36. Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D.R., Tessarollo, L., Casellas, R., Zhao, K. & Levens, D. (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell, 151, 68-79.
37. Niitsu, N., Okamoto, M., Miura, I. & Hirano, M. (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia, 23, 777-783.
38. Offit, K., Jhanwar, S.C., Ladanyi, M., Filippa, D.A. & Chaganti, R.S. (1991) Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer, 3, 189-201.
39. Oki, Y., Noorani, M., Lin, P., Davis, R.E., Neelapu, S.S., Ma, L., Ahmed, M., Rodriguez, M.A., Hagemeister, F.B., Fowler, N., Wang, M., Fanale, M.A., Nastoupil, L., Samaniego, F., Lee, H.J., Dabaja, B.S., Pinnix, C.C., Medeiros, L.J., Nieto, Y., Khouri, I., Kwak, L.W., Turturro, F., Romaguera, J.E., Fayad, L.E. & Westin, J.R. (2014) Double hit lymphoma: the MD Anderson Cancer Center clinical experience. British Journal of Haematology, 166, 891-901.
40. Ott, G., Rosenwald, A. & Campo, E. (2013) Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology/The Education Program of the American Society of Hematology, 2013, 575-583.
41. Parikh, K., Cang, S., Sekhri, A. & Liu, D. (2014) Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents. Journal of Hematology & Oncology, 7, 78.
42. Pedersen, M.O., Gang, A.O., Poulsen, T.S., Knudsen, H., Lauritzen, A.F., Nielsen, S.L., Gang, U.O. & Norgaard, P. (2012) Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience. European Journal of Haematology, 89, 63-71.
43. Pedersen, M.O., Gang, A.O., Poulsen, T.S., Knudsen, H., Lauritzen, A.F., Nielsen, S.L., Klausen, T.W. & Norgaard, P. (2014) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. European Journal of Haematology, 92, 42-48.
44. Perry, A.M., Crockett, D., Dave, B.J., Althof, P., Winkler, L., Smith, L.M., Aoun, P., Chan, W.C., Fu, K., Greiner, T.C., Bierman, P., Gregory Bociek, R., Vose, J.M., Armitage, J.O. & Weisenburger, D.D. (2013) B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. British Journal of Haematology, 162, 40-49.
45. Perry, A.M., Alvarado-Bernal, Y., Laurini, J.A., Smith, L.M., Slack, G.W., Tan, K.L., Sehn, L.H., Fu, K., Aoun, P., Greiner, T.C., Chan, W.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Vose, J.M., Gascoyne, R.D. & Weisenburger, D.D. (2014) MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. British Journal of Haematology, 165, 382-391.
46. Petrich, A.M., Gandhi, M., Jovanovic, B., Castillo, J.J., Rajguru, S., Yang, D.T., Shah, K.A., Whyman, J.D., Lansigan, F., Hernandez-Ilizaliturri, F.J., Lee, L.X., Barta, S.K., Melinamani, S., Karmali, R., Adeimy, C., Smith, S., Dalal, N., Nabhan, C., Peace, D., Vose, J., Evens, A.M., Shah, N., Fenske, T.S., Zelenetz, A.D., Landsburg, D.J., Howlett, C., Mato, A., Jaglal, M., Chavez, J.C., Tsai, J.P., Reddy, N., Li, S., Handler, C., Flowers, C.R., Cohen, J.B., Blum, K.A., Song, K., Sun, H.L., Press, O., Cassaday, R., Jaso, J., Medeiros, L.J., Sohani, A.R. & Abramson, J.S. (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood, 124, 2354-2361.
47. Puvvadda, S.D., Stiff, P.J., LeBlanc, M., Cook, J.R., Kahl, B.S., Li, H., Rimsza, L., Friedberg, J. & Smith, S. (2014) MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704. In: ASH Annual Meeting Abstracts. In press.
48. Savage, K.J., Johnson, N.A., Ben-Neriah, S., Connors, J.M., Sehn, L.H., Farinha, P., Horsman, D.E. & Gascoyne, R.D. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 114, 3533-3537.
49. Savage, K.J., Sehn, L.H., Villa, D., Kansara, R.R., Mottok, A., Ennishi, D., Ben-Neriah, S., Kridel, R., Steidl, C., Tan, K.L., Johnson, N.A., Slack, G.W., Connors, J.M., Farinha, P., Scott, D.W. & Gascoyne, R. (2014) The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) In: ASH Annual Meeting Abstracts. In press.
50. Sewastianik, T., Prochorec-Sobieszek, M., Chapuy, B. & Juszczynski, P. (2014) MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochimica et Biophysica Acta, 1846, 457-467.
51. Snuderl, M., Kolman, O.K., Chen, Y.B., Hsu, J.J., Ackerman, A.M., Dal Cin, P., Ferry, J.A., Harris, N.L., Hasserjian, R.P., Zukerberg, L.R., Abramson, J.S., Hochberg, E.P., Lee, H., Lee, A.I., Toomey, C.E. & Sohani, A.R. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. American Journal of Surgical Pathology, 34, 327-340.
52. Swerdlow, S.H., Campo, E., Lee Harris, N., Jaffe, E.S., PIleri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumors of the Hematopoeitic and Lymphoid Tissues. IARC, Lyon.
53. Tapia, G., Lopez, R., Munoz-Marmol, A.M., Mate, J.L., Sanz, C., Marginet, R., Navarro, J.T., Ribera, J.M. & Ariza, A. (2011) Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology, 59, 672-678.
54. Thangavelu, M., Olopade, O., Beckman, E., Vardiman, J.W., Larson, R.A., McKeithan, T.W., Le Beau, M.M. & Rowley, J.D. (1990) Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer, 2, 147-158.
55. Tibiletti, M.G., Martin, V., Bernasconi, B., Del Curto, B., Pecciarini, L., Uccella, S., Pruneri, G., Ponzoni, M., Mazzucchelli, L., Martinelli, G., Ferreri, A.J., Pinotti, G., Assanelli, A., Scandurra, M., Doglioni, C., Zucca, E., Capella, C. & Bertoni, F. (2009) BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Human Pathology, 40, 645-652.
56. Tomita, N., Tokunaka, M., Nakamura, N., Takeuchi, K., Koike, J., Motomura, S., Miyamoto, K., Kikuchi, A., Hyo, R., Yakushijin, Y., Masaki, Y., Fujii, S., Hayashi, T., Ishigatsubo, Y. & Miura, I. (2009) Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica, 94, 935-943.
57. Tzankov, A., Xu-Monette, Z.Y., Gerhard, M., Visco, C., Dirnhofer, S., Gisin, N., Dybkaer, K., Orazi, A., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W., van Krieken, J.H., Ponzoni, M., Ferreri, A.J., Ye, Q., Winter, J.N., Farnen, J.P., Piris, M.A., Moller, M.B., You, M.J., McDonnell, T., Medeiros, L.J. & Young, K.H. (2014) Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 27, 958-971.
58. Valera, A., Lopez-Guillermo, A., Cardesa-Salzmann, T., Climent, F., Gonzalez-Barca, E., Mercadal, S., Espinosa, I., Novelli, S., Briones, J., Mate, J.L., Salamero, O., Sancho, J.M., Arenillas, L., Serrano, S., Erill, N., Martinez, D., Castillo, P., Rovira, J., Martinez, A., Campo, E. & Colomo, L. (2013) MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica, 98, 1554-1562.
59. Visco, C., Tzankov, A., Xu-Monette, Z.Y., Miranda, R.N., Tai, Y.C., Li, Y., Liu, W.M., d'Amore, E.S., Li, Y., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Wang, H.Y., Dunphy, C.H., His, E.D., Zhao, X.F., Choi, W.W., Zhao, X., van Krieken, J.H., Huang, Q., Ai, W., O'Neill, S., Ponzoni, M., Ferreri, A.J., Kahl, B.S., Winter, J.N., Go, R.S., Dirnhofer, S., Piris, M.A., Moller, M.B., Wu, L., Medeiros, L.J. & Young, K.H. (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 98, 255-263.
60. Vitolo, U., Chiappella, A., Franceschetti, S., Carella, A.M., Baldi, I., Inghirami, G., Spina, M., Pavone, V., Ladetto, M., Liberati, A.M., Molinari, A.L., Zinzani, P., Salvi, F., Fattori, P.P., Zaccaria, A., Dreyling, M., Botto, B., Castellino, A., Congiu, A., Gaudiano, M., Zanni, M., Ciccone, G., Gaidano, G. & Rossi, G. (2014) Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. The Lancet Oncology, 15, 730-737.
61. Vose, J.M., Habermann, T.M., Czuczman, M.S., Zinzani, P.L., Reeder, C.B., Tuscano, J.M., Lossos, I.S., Li, J., Pietronigro, D. & Witzig, T.E. (2013) Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. British Journal of Haematology, 162, 639-647.
62. Walker, C.J., Oaks, J.J., Santhanam, R., Neviani, P., Harb, J.G., Ferenchak, G., Ellis, J.J., Landesman, Y., Eisfeld, A.K., Gabrail, N.Y., Smith, C.L., Caligiuri, M.A., Hokland, P., Roy, D.C., Reid, A., Milojkovic, D., Goldman, J.M., Apperley, J., Garzon, R., Marcucci, G., Shacham, S., Kauffman, M.G. & Perrotti, D. (2013) Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood, 122, 3034-3044.
63. Wang, M., Fowler, N., Wagner-Bartak, N., Feng, L., Romaguera, J., Neelapu, S.S., Hagemeister, F., Fanale, M., Oki, Y., Pro, B., Shah, J., Thomas, S., Younes, A., Hosing, C., Zhang, L., Newberry, K.J., Desai, M., Cheng, N., Badillo, M., Bejarano, M., Chen, Y., Young, K.H., Champlin, R., Kwak, L. & Fayad, L. (2013) Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia, 27, 1902-1909.
64. Witzig, T.E., Vose, J.M., Zinzani, P.L., Reeder, C.B., Buckstein, R., Polikoff, J.A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., Pietronigro, D., Ervin-Haynes, A.L. & Czuczman, M.S. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of Oncology, 22, 1622-1627.
65. Yan, L.X., Liu, Y.H., Luo, D.L., Zhang, F., Cheng, Y., Luo, X.L., Xu, J., Cheng, J. & Zhuang, H.G. (2014) MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One, 9, e104068.
66. Younes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J.W., Amorim, S., Hivert, B., Westin, J., Vermeulen, J., Bandyopadhyay, N., de Vries, R., Balasubramanian, S., Hellemans, P., Smit, J.W., Fourneau, N. & Oki, Y. (2014) Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. The Lancet Oncology, 15, 1019-1026.
67. Yunis, J.J., Oken, M.M., Theologides, A., Howe, R.B. & Kaplan, M.E. (1984) Recurrent chromosomal defects are found in most patients with non-Hodgkin's-lymphoma. Cancer Genetics and Cytogenetics, 13, 17-28.
68. Zhong, Y., El-Gamal, D., Dubovsky, J.A., Beckwith, K.A., Harrington, B.K., Williams, K.E., Goettl, V.M., Jha, S., Mo, X., Jones, J.A., Flynn, J.M., Maddocks, K.J., Andritsos, L.A., McCauley, D., Shacham, S., Kauffman, M., Byrd, J.C. & Lapalombella, R. (2014) Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia, 28, 1158-1163.
69. Zhou, M., Wang, J., Ouyang, J., Xu, J.Y., Chen, B., Zhang, Q.G., Zhou, R.F., Yang, Y.G., Shao, X.Y., Xu, Y., Chen, Y.M., Fan, X.S. & Wu, H.Y. (2014) MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. Tumour Biology, 35, 6757-6762.
70. Zinzani, P.L., Pellegrini, C., Gandolfi, L., Stefoni, V., Quirini, F., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S. & Baccarani, M. (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clinical Lymphoma, Myeloma & Leukemia, 11, 462-466.